V-Bio Ventures

The rise of women’s health

It’s been a Barbie world this summer with crowds of pink-clad moviegoers flooding the cinemas. Simultaneously, we’ve been witnessing a […] November 15, 2023 · V-Bio Ventures

Muna Therapeutics: hopeful solutions for memory loss

Muna Therapeutics is developing transformative therapies for neurodegenerative diseases. These drugs aim to preserve cognition and enhance the brain’s resilience […] October 17, 2023 · V-Bio Ventures

V-Bio Ventures Portfolio Company Agomab Raises $100 Million Series C to Advance Fibrosis-focused Pipeline

— Round led by Fidelity Management & Research Company with participation from new investors EQT Life Sciences, Canaan and Dawn […] October 11, 2023 · V-Bio Ventures

Lean years for company creation in Europe?

After an exceptional sequence of socio-economic shocks over the past few years, the number of new companies being formed in […] September 27, 2023 · V-Bio Ventures

V-Bio Ventures portfolio company Orionis Biosciences announces collaboration with Genentech to discover and develop molecular glue class medicines

September 20, 2023, BOSTON, MA and GHENT, Belgium – Orionis Biosciences, a privately held life sciences company with an integrated […] September 20, 2023 · V-Bio Ventures

V-Bio Ventures portfolio company Corteria Pharmaceuticals raises EUR 65 million to advance its transformational medicines for cardiovascular diseases

Ghent, Belgium, 7 September 2023 – Corteria Pharmaceuticals, a V-Bio Ventures portfolio company, is a biopharmaceutical company specialized in the […] September 7, 2023 · V-Bio Ventures

Fermenting a more sustainable future

In the battle against the climate crisis, precision fermentation presents a hopeful aid. Using microbes to create valuable materials, we […] August 23, 2023 · V-Bio Ventures

The obesity revolution: will new drugs bring about big changes?

The recent approval of the obesity and diabetes drugs Wegovy, Ozempic, and Mounjaro has brought about big headlines, but are […] June 21, 2023 · V-Bio Ventures

Fake it till you fund it?

Silicon Valley investment gurus have long promoted the idea that startups should ‘fake it till you make it’ to become […] May 24, 2023 · V-Bio Ventures

V-Bio Ventures portfolio company Dualyx raises €40 million to progress Treg therapies for autoimmune diseases into the clinic

Use of proceeds will enable the development of the Company’s lead autoimmune program DT-001, targeting TNFR2, as well as its […] May 15, 2023 · V-Bio Ventures

Corteria: a new strategy and approach to treating heart failure

Corteria Pharmaceuticals is developing transformative therapies for heart failure subpopulations most likely to benefit from the company’s novel cardiorenal treatments. […] April 25, 2023 · V-Bio Ventures

Are we at the end of the biotech boom cycle?

Bankruptcy, closures, and layoffs – oh my! But it’s not all doom and gloom for the biotech boom. Innovation is still […] March 29, 2023 · V-Bio Ventures

V-Bio Ventures portfolio company Confo Therapeutics Announces Global Licensing Agreement with Lilly for Peripheral Pain Candidate, CFTX-1554

Confo to receive upfront and milestone payments totaling $630M Company is eligible for up to $590M in additional milestones if […] March 2, 2023 · V-Bio Ventures

The hype cycle in life sciences investments: go with the flow or fight the current?

Everyone in the investment business is familiar with the phenomenon of technology hypes. These trends tend to come and go […] February 22, 2023 · V-Bio Ventures

Coave Therapeutics: redecorating viral vectors for improved gene therapies

Coave Therapeutics is a French biotech developing gene therapies for neurodegenerative and ocular diseases. The company has developed a technology […] January 25, 2023 · V-Bio Ventures